BR112017002930A2 - ?métodos de tratamento de depressão usando moduladores de nmda? - Google Patents

?métodos de tratamento de depressão usando moduladores de nmda?

Info

Publication number
BR112017002930A2
BR112017002930A2 BR112017002930A BR112017002930A BR112017002930A2 BR 112017002930 A2 BR112017002930 A2 BR 112017002930A2 BR 112017002930 A BR112017002930 A BR 112017002930A BR 112017002930 A BR112017002930 A BR 112017002930A BR 112017002930 A2 BR112017002930 A2 BR 112017002930A2
Authority
BR
Brazil
Prior art keywords
methods
treating depression
nmda modulators
nmda
modulators
Prior art date
Application number
BR112017002930A
Other languages
English (en)
Inventor
Burch Ron
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of BR112017002930A2 publication Critical patent/BR112017002930A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

esta divulgação fornece métodos e regimes para tratar depressão (por exemplo, depressão resistente a tratamento) em um paciente (por exemplo, um paciente com necessidade de tal tratamento).
BR112017002930A 2014-08-14 2015-08-13 ?métodos de tratamento de depressão usando moduladores de nmda? BR112017002930A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14
PCT/US2015/045071 WO2016025721A1 (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Publications (1)

Publication Number Publication Date
BR112017002930A2 true BR112017002930A2 (pt) 2017-12-05

Family

ID=55304631

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002930A BR112017002930A2 (pt) 2014-08-14 2015-08-13 ?métodos de tratamento de depressão usando moduladores de nmda?

Country Status (18)

Country Link
US (1) US20170296616A1 (pt)
EP (1) EP3180015A4 (pt)
JP (2) JP2017524721A (pt)
KR (1) KR20170040351A (pt)
CN (1) CN106659763A (pt)
AU (2) AU2015301650A1 (pt)
BR (1) BR112017002930A2 (pt)
CA (1) CA2957937A1 (pt)
CL (1) CL2017000378A1 (pt)
CO (1) CO2017002356A2 (pt)
IL (1) IL250557A0 (pt)
MX (1) MX2017002052A (pt)
PH (1) PH12017500275A1 (pt)
RU (1) RU2017107033A (pt)
SG (2) SG10201810016XA (pt)
UA (1) UA123623C2 (pt)
WO (1) WO2016025721A1 (pt)
ZA (1) ZA201701526B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
WO2018098344A1 (en) * 2016-11-28 2018-05-31 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
EP3706734A1 (en) * 2017-11-10 2020-09-16 Naurex Inc. Methods of administration of nmda receptor agonists
BR112020011401A2 (pt) * 2017-12-05 2020-11-24 Naurex Inc. combinação de moduladores de receptor nmda (rapastinel) para uso em tratamento combinado (distúrbio do sono e do snc)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
RS53513B1 (en) * 2009-10-05 2015-02-27 Northwestern University GLYX-13 FOR USE IN THE REFRACTOR DEPRESSION TREATMENT PROCEDURE
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans

Also Published As

Publication number Publication date
WO2016025721A1 (en) 2016-02-18
CN106659763A (zh) 2017-05-10
CA2957937A1 (en) 2016-02-18
US20170296616A1 (en) 2017-10-19
AU2015301650A1 (en) 2017-03-23
RU2017107033A3 (pt) 2019-02-12
CL2017000378A1 (es) 2017-11-03
ZA201701526B (en) 2018-05-30
AU2020203165A1 (en) 2020-06-04
SG10201810016XA (en) 2018-12-28
JP2020128391A (ja) 2020-08-27
SG11201701134XA (en) 2017-03-30
PH12017500275A1 (en) 2017-07-03
JP2017524721A (ja) 2017-08-31
EP3180015A4 (en) 2018-02-14
KR20170040351A (ko) 2017-04-12
UA123623C2 (uk) 2021-05-05
RU2017107033A (ru) 2018-09-14
CO2017002356A2 (es) 2017-06-09
MX2017002052A (es) 2018-08-15
IL250557A0 (en) 2017-03-30
EP3180015A1 (en) 2017-06-21

Similar Documents

Publication Publication Date Title
PH12018501656A1 (en) Methods for using fxr agonists
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
PH12017500275A1 (en) Methods of treating depression using nmda modulators
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
SG10201900574SA (en) Virtual currency conversion device, method and computer program
MX2015011606A (es) Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
IL260684B (en) Treatment to regulate the microbiota in the intestine
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MA40364A (fr) Polythérapie pour le traitement du cancer
BR112017006515A2 (pt) moléculas biespecíficas, composições, método para tratar ou prevenir infecção por hiv-1 em um indivíduo com essa necessidade, e vetor
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2021006326A (es) Inhibidores de pcna.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2020011946A (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamin a (nmda).
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2683 DE 07-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.